Rainer Boxhammer

451 total citations
26 papers, 322 citations indexed

About

Rainer Boxhammer is a scholar working on Oncology, Genetics and Hematology. According to data from OpenAlex, Rainer Boxhammer has authored 26 papers receiving a total of 322 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 11 papers in Genetics and 11 papers in Hematology. Recurrent topics in Rainer Boxhammer's work include Chronic Lymphocytic Leukemia Research (10 papers), Multiple Myeloma Research and Treatments (10 papers) and Peptidase Inhibition and Analysis (7 papers). Rainer Boxhammer is often cited by papers focused on Chronic Lymphocytic Leukemia Research (10 papers), Multiple Myeloma Research and Treatments (10 papers) and Peptidase Inhibition and Analysis (7 papers). Rainer Boxhammer collaborates with scholars based in Germany, United States and Austria. Rainer Boxhammer's co-authors include Jan Endell, Stefan Steidl, Pedro Horna, Grzegorz S. Nowakowski, Daniel Ness, Cornelia Wurzenberger, Johannes Weirather, Hermine Agis, Barbara Ferstl and Christoph Röllig and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of the American Society of Nephrology.

In The Last Decade

Rainer Boxhammer

26 papers receiving 317 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rainer Boxhammer Germany	11	166	155	85	82	77	26	322
Wolf Hassenpflug Germany	9	219 1.3×	50 0.3×	52 0.6×	255 3.1×	46 0.6×	16	401
Raquel Jiménez Spain	6	327 2.0×	171 1.1×	14 0.2×	63 0.8×	189 2.5×	14	381
Márk Plander Hungary	8	56 0.3×	82 0.5×	56 0.7×	66 0.8×	87 1.1×	23	241
E. Emmett United Kingdom	7	49 0.3×	126 0.8×	71 0.8×	217 2.6×	48 0.6×	7	447
Stephan Bohl Germany	8	159 1.0×	56 0.4×	4 0.0×	89 1.1×	176 2.3×	16	329
Stéphanie Guidez France	10	170 1.0×	155 1.0×	38 0.4×	57 0.7×	126 1.6×	45	387
A McClure United Kingdom	3	39 0.2×	137 0.9×	139 1.6×	123 1.5×	59 0.8×	4	362
Shih‐Shih Chen United States	12	76 0.5×	118 0.8×	24 0.3×	236 2.9×	126 1.6×	41	494
Aneta Schieferdecker Germany	7	40 0.2×	96 0.6×	33 0.4×	28 0.3×	83 1.1×	17	203
RA Kyle United States	9	436 2.6×	207 1.3×	43 0.5×	45 0.5×	309 4.0×	9	503

Countries citing papers authored by Rainer Boxhammer

Since Specialization

Citations

This map shows the geographic impact of Rainer Boxhammer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rainer Boxhammer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rainer Boxhammer more than expected).

Fields of papers citing papers by Rainer Boxhammer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rainer Boxhammer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rainer Boxhammer. The network helps show where Rainer Boxhammer may publish in the future.

Co-authorship network of co-authors of Rainer Boxhammer

This figure shows the co-authorship network connecting the top 25 collaborators of Rainer Boxhammer. A scholar is included among the top collaborators of Rainer Boxhammer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rainer Boxhammer. Rainer Boxhammer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ilieva, Kristina M., et al.. (2024). Felzartamab Selectively and Potently Targets CD38+ Antibody-Secreting Cells from Patients with Immune-Mediated Kidney Diseases. Journal of the American Society of Nephrology. 35(10S). 1 indexed citations

Barratt, Jonathan, Rainer Boxhammer, Brian S. Schwartz, et al.. (2024). Felzartamab Durably Reduces Disease-Relevant Biomarkers through Targeting of CD38+ Plasma Cells and Plasmablasts, the Upstream Drivers of IgAN. Journal of the American Society of Nephrology. 35(10S). 1 indexed citations

Rovin, Brad H., Pierre Ronco, Jack F.M. Wetzels, et al.. (2024). Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody–Positive Primary Membranous Nephropathy. Kidney International Reports. 9(9). 2635–2647. 12 indexed citations

Ilieva, Kristina M., Markus Eberl, Jan Jaehrling, et al.. (2023). Preclinical study of CD19 detection methods post tafasitamab treatment. Frontiers in Immunology. 14. 3 indexed citations

Boxhammer, Rainer, et al.. (2023). Felzartamab Reduces aPLA2R Ab by Selectively Depleting CD38+ Plasma Cells and Plasmablasts, the Main Pathogenic Cellular Drivers of Disease in Primary Membranous Nephropathy (PMN). Journal of the American Society of Nephrology. 34(11S). 982–982. 1 indexed citations

Drescher, Charles W., Harriet S. Walter, Elvire Pons‐Tostivint, et al.. (2023). PR088/#198 EZH2/EZH1 inhibitor tulmimetostat (CPI-0209): preliminary phase II results and first biomarker findings in patients with arid1a-mutant ovarian clear cell or endometrial carcinomas (OCCC/EC). A80.1–A80. 1 indexed citations

Mayer, Katharina A., Klemens Budde, Philip F. Halloran, et al.. (2022). Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial. Trials. 23(1). 270–270. 15 indexed citations

Her, Jung Hyun, Yu Kyeong Hwang, Timm Hoeres, et al.. (2022). Tafasitamab mediates killing of B-cell non-Hodgkin’s lymphoma in combination with γδ T cell or allogeneic NK cell therapy. Cancer Immunology Immunotherapy. 71(11). 2829–2836. 9 indexed citations

Rovin, Brad H., et al.. (2022). Immunologic Responses After COVID-19 Vaccination in Patients With Membranous Nephropathy Receiving Anti–CD38 Felzartamab Therapy: Results From the Phase 1b/2a M-PLACE Study. Kidney International Reports. 7(9). 2086–2090. 6 indexed citations

10.

Rovin, Brad H., Sharon G. Adler, Elion Hoxha, et al.. (2021). Felzartamab in Patients with Anti-Phospholipase A2 Receptor Autoantibody Positive (Anti-PLA2R+) Membranous Nephropathy (MN): Interim Results from the M-PLACE Study. Journal of the American Society of Nephrology. 32(10S). 513–514. 1 indexed citations

11.

Her, Jung Hyun, Sungyoo Cho, Yu Kyeong Hwang, et al.. (2019). Functional Characterization of Gamma Delta T Cells and Allogeneic Activated NK Cells As Effector Cells for Tafasitamab (MOR208). Blood. 134(Supplement_1). 3801–3801. 1 indexed citations

12.

Horna, Pedro, Grzegorz S. Nowakowski, Jan Endell, & Rainer Boxhammer. (2019). Comparative Assessment of Surface CD19 and CD20 Expression on B-Cell Lymphomas from Clinical Biopsies: Implications for Targeted Therapies. Blood. 134(Supplement_1). 5345–5345. 35 indexed citations

13.

Chatterjee, Manik, Marc S. Raab, Hartmut Goldschmidt, et al.. (2017). A phase I/IIa Study of the CD38 Antibody MOR202 in Combination With Pomalidomide or Lenalidomide in Patients With Relapsed or Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 17(1). e61–e61. 20 indexed citations

14.

Boxhammer, Rainer, Johannes Weirather, Stefan Steidl, & Jan Endell. (2015). MOR202, a Human Anti-CD38 Monoclonal Antibody, Mediates Potent Tumoricidal Activity In Vivo and Shows Synergistic Efficacy in Combination with Different Antineoplastic Compounds. Blood. 126(23). 3015–3015. 20 indexed citations

15.

Boxhammer, Rainer, Stefan Steidl, & Jan Endell. (2015). Effect of IMiD compounds on CD38 expression on multiple myeloma cells: MOR202, a human CD38 antibody in combination with pomalidomide.. Journal of Clinical Oncology. 33(15_suppl). 8588–8588. 24 indexed citations

16.

Seidl, Christof, Birgit Blechert, Florian Gaertner, et al.. (2014). α-Radioimmunotherapy with 213Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma. Oncotarget. 6(7). 4692–4703. 38 indexed citations

17.

Endell, Jan, Rainer Boxhammer, & Stefan Steidl. (2014). Synergistic in Vitro Activity of MOR202, a Human CD38 Antibody, in Combination with Pomalidomide. Blood. 124(21). 5712–5712. 8 indexed citations

18.

Endell, Jan, Rainer Boxhammer, Cornelia Wurzenberger, Daniel Ness, & Stefan Steidl. (2012). The Activity of MOR202, a Fully Human Anti-CD38 Antibody, Is Complemented by ADCP and Is Synergistically Enhanced by Lenalidomide in Vitro and in Vivo. Blood. 120(21). 4018–4018. 31 indexed citations

19.

Giblin, Patricia, Rainer Boxhammer, Sudha Desai, et al.. (2011). Fully human antibodies against the Protease-Activated Receptor-2 (PAR-2) with anti-inflammatory activity. Human Antibodies. 20(3-4). 83–94. 9 indexed citations

20.

Endell, Jan, Christina Samuelsson, Rainer Boxhammer, Sandra J. Strauss, & Stefan Steidl. (2011). Effect of MOR202, a human CD38 antibody, in combination with lenalidomide and bortezomib, on bone lysis and tumor load in a physiologic model of myeloma.. Journal of Clinical Oncology. 29(15_suppl). 8078–8078. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact